Citadel Advisors
RVMD icon

Citadel Advisors’s Revolution Medicines RVMD Stock Holding History

Citadel Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.7M Buy
274,900
+151,100
+122% +$15.3M ﹤0.01% 1979
2025
Q4 		$9.86M Buy
123,800
+68,500
+124% +$4.49M ﹤0.01% 3276
2025
Q3 		$2.58M Sell
55,300
-6,900
-11% -$270K ﹤0.01% 5572
2025
Q2 		$2.29M Buy
62,200
+30,100
+94% +$1.16M ﹤0.01% 5455
2025
Q1 		$1.14M Sell
32,100
-35,500
-53% -$1.44M ﹤0.01% 6690
2024
Q4 		$2.96M Buy
67,600
+56,900
+532% +$2.87M ﹤0.01% 4860
2024
Q3 		$485K Sell
10,700
-3,600
-25% -$157K ﹤0.01% 8321
2024
Q2 		$555K Sell
14,300
-6,911
-33% -$258K ﹤0.01% 7843
2024
Q1 		$684K Sell
21,211
-25,321
-54% -$750K ﹤0.01% 7715
2023
Q4 		$1.33M Buy
46,532
+34,132
+275% +$820K ﹤0.01% 6100
2023
Q3 		$343K Buy
12,400
+200
+2% +$5.93K ﹤0.01% 8886
2023
Q2 		$326K Buy
12,200
+5,000
+69% +$123K ﹤0.01% 8866
2023
Q1 		$156K Buy
7,200
+4,900
+213% +$121K ﹤0.01% 10576
2022
Q4 		$54.8K Sell
2,300
-52,600
-96% -$1.12M ﹤0.01% 12017
2022
Q3 		$1.08M Buy
+54,900
New +$1.21M ﹤0.01% 6831
2022
Q1 		– Sell
-35,200
Closed -$886K – 14443
2021
Q4 		$886K Buy
35,200
+24,200
+220% +$682K ﹤0.01% 8249
2021
Q3 		$303K Sell
11,000
-5,000
-31% -$146K ﹤0.01% 11048
2021
Q2 		$508K Buy
16,000
+8,200
+105% +$286K ﹤0.01% 10029
2021
Q1 		$358K Buy
+7,800
New +$350K ﹤0.01% 10439

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's RVMD Position: Q1 2026 in Review

Citadel Advisors reduced its Revolution Medicines (RVMD) stake by 69% in Q1 2026, selling an estimated $91.1M and leaving 400,053 shares worth $38.9M. The position accounts for 0.01% of the portfolio, ranked #1594.

Citadel Advisors first reported a position in RVMD in Q1 2020 and has held it in 24 quarters since. The position peaked at $104M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Citadel Advisors held 400,053 shares of Revolution Medicines worth $38.9M as of Q1 2026.
  • Citadel Advisors sold 902,308 Revolution Medicines shares in Q1 2026, an estimated $91.1M.
  • Revolution Medicines made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1594 holding.
  • Citadel Advisors first reported a position in Revolution Medicines in Q1 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Revolution Medicines position peaked at $104M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.